美国人类基因组科学公司（Human Genome Sciences, Inc.）
人类基因组科学公司，简称HGSI，是一个开发以新蛋白质和基因为主的生技药物新兴公司。 HGS公司成立于1992年，自创立以来致力于人类基因的搜寻和研究，至1999年6月止，HGS已发现及获得6,450个人类基因和相关医疗应用的商业专利。目前，HGS公司已有三项基因药物进入人体临床实验阶段，分别为KGF-2、MPIF-1、和VEFG-2。其中的两项(MPIF-1 及KGF-2)的作用为保护正常细胞，降低癌症病患所受到化学治疗的不适和排斥现象。 MPIF-1的全名为Myeloid Progenitor Inhibitory Factor-1，是一种具有保护造血细胞功能的蛋白质。 KGF-2的全名为Keratinocyte Growth Factor-2，主要功能是修补表皮细胞和粘膜层，有利于慢性或溃烂性伤口的愈合。第三种临床用药-VEGF-2的全名为Vascular Endothelial Growth Factor-2，具有在心脏和四肢血管再造的功能。对于VEGF-2的开发，目前HGS是以和Vascular Genetics Inc (血管基因公司)合作的形式进行。

人类基因组科学公司(HGS Inc.)的资金来源主要是由其商业投资者和数家大型药厂所提供。至今，HGS公司已定期从多家生技药商收取其基因专利使用权利金。因此与多家新兴生技公司相较之下，其经费来源相当稳定。

人类基因科学公司的总部目前位于马理兰州的洛克维尔(Rockville)市， 现有原工327人。公司股票在拿斯达克(NASDAQ)店头市场挂牌， 股名为"HGSI"。以新兴公司集资能力而言，HGS公司表现相当优秀。公司的总资产估计约8.5亿美元，上市第一年的股价曾由15美元上升到超过200美元， 在人类基因组序码被破解的热潮时, 聚集了相当可观的资本。


   

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

Late-Stage Products

We are poised for the market with a clinical pipeline that includes three novel products in late-stage development:

BENLYSTA™ (belimumab) has successfully completed Phase 3 development in systemic lupus, and we expect the submission of marketing applications in the United States, Europe and other regions in the first half of 2010.
ZALBIN™ (albinterferon alfa-2b) has successfully completed Phase 3 development in chronic hepatitis C. We have submitted a Biologics License Application to the FDA for ZALBIN in the United States, and we expect submission of marketing authorization applications soon in other regions of the world, beginning with Europe in fourth quarter 2009.
In May 2009, we filed a Biologics License Application for raxibacumab with FDA for inhalational anthrax.
We believe both BENLYSTA and ZALBIN have the therapeutic potential to change and save lives and, assuming regulatory approval, the commercial potential to become leading products in the marketplace. Each is being co-developed and commercialized in collaboration with a world leader in the pharmaceutical industry – GlaxoSmithKline (GSK) for BENLYSTA and Novartis for ZALBIN.

Raxibacumab is being developed under a contract with the U.S. Government and represents a new way to address the threat of inhalational anthrax. In April 2009, we completed the delivery of 20,000 doses of raxibacumab to the U.S. Strategic National Stockpile for use in the event of an emergency to treat inhalational anthrax. In July 2009, we secured a new purchase order for 45,000 doses of raxibacumab to be delivered to the Stockpile over a three-year period beginning near the end of 2009.

Mid-Stage Pipeline

Right behind these three late-stage products is a high-potential mid-stage pipeline led by mapatumumab, our TRAIL receptor antibody for cancer. We also have substantial financial rights to a number of products in the GSK pipeline. GSK has initiated Phase 3 clinical trials of darapladib in men and women with chronic coronary heart disease, and Syncria® (albiglutide) in type 2 diabetes.

Manufacturing and Process Development

Our manufacturing and process development capability represents a significant strategic advantage. HGS is able to produce and purify multiple protein and antibody drugs in two state-of-the-art process development and manufacturing facilities – totaling approximately 400,000 square feet and offering both small-scale and large-scale production.

Strong Cash Position

Unlike many pre-commercial biopharmaceutical companies, HGS has built a strong cash position that allows us to focus on advancing our lead products toward commercialization as rapidly as possible, while at the same time investing in our early- and mid-stage pipeline. We are committed to achieving and sustaining growth well into the future.